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Abstract—The possibility of reopening an occluded cerebral artery by means of thrombolysis has renewed interest in a
number of the several mechanisms that are active during acute cerebral ischemia. Over recent years, it has become
apparent that leukocytes play a central role not only during the healing stage of brain infarction but also during the early
phases of cerebral ischemia, when it is postulated that these cells produce harmful effects, particularly in the presence
of reperfusion. This review is based on the critical analysis of more than 150 publications dealing with the role of
leukocytes and some inflammatory mediators (cytokines, chemokines, and adhesion molecules) in cerebral ischemia.
Animal studies indicate that leukocyte involvement is promoted by a variety of inflammatory molecules produced
immediately after the onset of cerebral ischemia. Considerable experimental evidence suggests that these mediators play
a key role in the progression from ischemia to irreversible injury (ie, cellular death and necrosis). However, the precise
role of each molecule alone remains to be further elucidated as well as in relation to the complex network existing among
different mediators. Progress in our understanding of the inflammatory mechanisms operating in cerebral ischemia has
enabled the testing of new compounds with promising results in animals; in contrast, one recent controlled trial of an
anti-leukocyte molecule in acute stroke patients showed negative results. This discrepancy may derive in part from our
incomplete understanding of the complexity of the inflammatory mechanisms involved in cerebral ischemia. Our
analysis suggests that until sufficient knowledge of the underlying disease mechanisms is acquired, more care should
be taken when testing new and potentially efficacious drugs in stroke patients.
The scenario of acute ischemic stroke therapy is rapidlyevolving, and thrombolysis has recently been approved
for use in stroke patients by USA authorities. However,
therapeutic recanalization of an occluded cerebral artery still
appears to be a potentially risky option that can be applied
only in the case of selected patients.1,2 The main limitation of
cerebral thrombolysis is the narrow, 3-hour therapeutic “win-
dow” during which the thrombolytic agent has to be admin-
istered to be effective3; beyond this time limit, its effective-
ness is neutralized by the high risk of cerebral hemorrhage.4
The rationale for the use of a number of other pharmaco-
logical treatments for acute stroke currently under study in
both animals and humans is based on recent advances in the
pathophysiology of brain ischemia, one of the most rapidly
expanding and promising areas of which is the role of
inflammation in stroke. This role involves (1) the molecules
that form part of the inflammatory response and participate in
the pathophysiological cascade after an ischemic insult and
(2) the inflammatory or infectious processes that may predis-
pose or precipitate atherothrombotic stroke.5–8 In this review,
we reexamine some aspects of inflammation in acute stroke
by focusing on the role of leukocytes and leukocyte-related
molecules, with the aim of providing the background neces-
sary to understand the rationale of newly emerging therapeu-
tic approaches. Our review is limited to experimental and
human data concerning some of the inflammatory mecha-
nisms active during the acute phase of cerebral ischemia.
Histological Inflammatory Aspects in Acute
Cerebral Ischemia
An inflammatory reaction is a common response of the brain
parenchyma to various forms of insult. It is histologically
characterized by the infiltration of leukocytes, which in the
case of cerebral ischemia are mainly polymorphonuclear
leukocytes and monocytes/macrophages.9 Human data are
scarce: an increased number of leukocytes has been docu-
mented in the cerebrospinal fluid of acute stroke patients 2 to
3 days after stroke10; a high number of radiolabeled poly-
morphonuclear leukocytes have been shown in slightly per-
fused brain areas as early as 6 to 12 hours after the ictus11; and
one autopsy study described intense leukocyte infiltration of
the brain parenchyma 2 to 3 days after the stroke.12
However, the inflammatory response of ischemic brain
parenchyma has been more thoroughly explored in animal
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models. An increased number of polymorphonuclear leuko-
cytes in the microvessels or ischemic brain parenchyma have
been found in various species.13–21 Until recently, it was
assumed that this inflammatory reaction was delayed, sec-
ondary to tissue necrosis, and was intended to remove tissue
debris from the infarcted area. In rats with permanent occlu-
sion of one MCA, leukocytes (particularly polymorphonu-
clear cells) can be recognized in the microvessels as early as
30 minutes after occlusion.22 In the same model, necrosis is
detected only 72 to 96 hours after MCA occlusion.23,24 This
study and others suggest that at least the early arrival of
leukocytes in the brain parenchyma is independent of the
presence of necrosis, and this idea leads to the hypothesis that
these cells play a role in the progression from ischemia to
brain infarction.
There are a number of mechanisms by which leukocytes
may produce deleterious effects on ischemic parenchyma. It
has been proposed that leukocytes obstruct the microvessels
and contribute toward the so-called “no-reflow” phenome-
non16: ie, the lack of complete recovery of cerebral blood flow
in the ischemic area after reperfusion.25 This plugging of
microvessels under ischemic conditions may be the result of
an interaction with endothelial cells, mediated by adhesion
molecules and/or the loss of cell deformability due to actin
polymerization and pseudopod projections.26,27 As reviewed
by Ha¨rtl et al,28 other detrimental effects of leukocytes during
ischemia may be due to: (1) the release of vasoconstrictive
mediators, such as superoxidase anions, thromboxane A2,
endothelin-1, and prostaglandin H2 29; (2) an alteration in
cerebral artery vasoreactivity; and (3) the release of cytotoxic
enzymes, free oxygen radicals, NO, and products of the
phospholipid cascade. The release of proteolytic enzymes
such as elastase might damage endothelial cell membranes
and the basal lamina, alter the blood-brain barrier, and
contribute to the formation of postischemic edema. In addi-
tion, loss of the integrity of the endothelial cell–basal lamina
lining might facilitate the escape of red blood cells and the
hemorrhagic transformation of a brain infarct.30,31
The view that leukocytes may cause additional damage to
potentially still-viable tissue during acute cerebral ischemia is
indirectly supported by data showing a smaller infarct volume
in neutropenic animals than in normal controls.32–35 Further-
more, a significant correlation has been found in humans
between the degree of leukocyte accumulation and infarct
volume as assessed by CT.11 The arrival of leukocytes in the
ischemic area is a multistep process.36 They first marginate in
the venules, then adhere to endothelial cells, and finally
migrate into the brain parenchyma. During each of these three
steps, their functions are regulated by the inflammation-
related molecules that are produced soon after the onset of
cerebral ischemia.
Cytokines and Cerebral Ischemia
The signals mediating the entry of leukocytes into the
ischemic area have not yet been completely elucidated, but a
number of clues suggest that cytokines play a key role in this
process. Cytokines are low-molecular-weight glycoproteins
that act as intercellular messengers and are produced by
macrophages, monocytes, lymphocytes, endothelial cells, fi-
broblasts, platelets, and many other cell types. To produce
cytokines, all of these cells need to be activated.37 Cytokines
act at very low concentrations on specific target-cell recep-
tors, whose expression is modulated by the cytokines them-
selves. Binding of cytokines to receptors activates intracellu-
lar second-messenger systems (yet to be identified) and
subsequently, protein kinases and phosphatases. These pro-
teins cause gene regulation through the activity of transcrip-
tion factors.37 Cytokines are considered to be among the
principal mediators of immunologic and inflammatory re-
sponses. In vitro, cytokines can be produced by astrocytes,
neurons, and endothelial and microglia cells,38–40 and there
are observations suggesting that this also holds true in
humans affected by brain ischemia.41
Cytokines may have various functions during cerebral
ischemia: on the one hand, they can attract leukocytes and
stimulate the synthesis of adhesion molecules in leukocytes,
endothelial cells, and other cells, thus promoting the inflam-
matory response of damaged cerebral tissue; on the other,
they can facilitate thrombogenesis by increasing the levels of
plasminogen-activating inhibitor-1, tissue factor, and plate-
let-activating factor42,43 and by inhibiting tissue plasminogen
activator and protein S.44 Examination of this last aspect is
beyond the scope of the present review.
IL-1
IL-1 exists in two separate forms (a and b), which have only
one-third sequence homology. IL-1 is overexpressed during
brain ischemia, as documented by the induction of IL-1b
mRNA synthesis in rats with permanent MCA occlusion,45,46
transient global forebrain ischemia,47–50 or a ligated carotid
artery associated with hypoxia.51 Attempts to detect IL-1 in
the peripheral blood of stroke patients have so far been
unsuccessful, conceivably because of its low plasma levels.52
Evidence that IL-1 may play a deleterious role in cerebral
ischemia derives from the observation that rats with a
transient MCA occlusion have a larger brain infarction when
recombinant human IL-1b is injected into the lateral ventricle
immediately after reperfusion.53 Similar results have been
obtained in rats with a permanent MCA occlusion.54 The
intraventricular injection of recombinant human IL-1b also
enhances the formation of brain edema and increases both the
number of neutrophils in ischemic areas and neutrophil–en-
dothelial cell adhesion.53 The complex functions of IL-1 are
mediated by specific cell-surface receptors and regulated by
the IL-1 receptor antagonist.55 Two main receptors for IL-1
have been identified; type I is present in many cell types and
Selected Abbreviations and Acronyms
CINC 5 cytokine-induced neutrophil chemoattractant
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binds IL-1a and IL-1b with similar affinity.56 Type II is found
on the surface of B cells, neutrophils, and macrophages and
shows higher affinity for IL-1b.56 Types I and II are regulated
differently in brain ischemia and may thus play separate roles.
In spontaneously hypertensive rats, the mRNA for the type I
IL-1 receptor is relatively highly expressed in the normal
cortex, with a marked increase 5 days after cerebral ische-
mia.55 Type II mRNA has low basal expression and a peak 12
hours after the onset of ischemia.55 The possible mechanisms
of intracellular signal transduction for IL-1 on peripheral
immune cells include effects on cAMP, protein kinase C, and
protein phosphorylation56; these effects remain to be proved
in brain ischemia. The IL-1–receptor interaction is quickly
followed by the induction of immediate-early genes such as
c-jun and c-fos.57
Studies showing a reduction in infarct size after the
administration of IL-1 antagonists or inhibitors provide fur-
ther evidence of the importance of IL-1 in cerebral ische-
mia.53,58–64 The possible harmful mechanisms induced or
activated by IL-1 include fever, increased heart rate and
arterial blood pressure, enhancement of N-methyl-D-aspar-
tate–mediated injury, proliferation of microglia, release of
arachidonic acid, and stimulation of NO synthesis.65 At
present, the most widely recognized functions of IL-1 appear
to be the induction of endothelial cell adhesion molecule
expression and the promotion of neutrophil tissue infiltration.
TNF-a
TNF-a gene upregulation has been demonstrated in tran-
sient66 and prolonged51,67 cerebral ischemia by the increased
synthesis of TNF-a mRNA in the parenchyma. TNF-a
plasma levels have also been found to be higher in acute
stroke patients than in healthy control subjects.68
The effects of TNF-a are mediated by specific receptors,
the most well known of which are two proteins called p75 and
p55 (according to their molecular weight).69 The binding of
TNF-a to its receptor is followed by the activation of a
variety of proteins, such as protein kinase C, tyrosine kinase,
mitogen-activated protein kinase, phospholipase A2, and
phosphatidylcholine-specific phospholipase C.70 Among
these, the mitogen-activated protein kinases are the most
extensively studied, and they are divided into three main
families: (1) the extracellular signal–regulated kinases, which
are activated by growth factors; (2) the c-Jun NH2-terminal
kinases; and (3) the p38 kinases. The last two groups are
activated by proinflammatory cytokines.71,72 The second step
in the TNF-a signal transduction pathway, as for other
cytokines, is intranuclear, with the activation of several
transcription factors. One of these, nuclear factor-kB, trans-
locates from the cytoplasm to the nucleus, where it activates
the promoter of the genes for adhesion molecules and other
cytokines.73
Like IL-1, TNF-a induces the expression of adhesion
molecules by glial and endothelial cells,74 thus favoring
neutrophil adherence and accumulation in microvessels.67
TNF-a is also involved in blood-brain barrier alterations, a
proadhesive-procoagulant transformation of endothelial cell
surfaces, and glial cell activation.74 However, its role in
cerebral ischemia remains to be established. Barone et al75
showed that administration of TNF-a exacerbated the ische-
mic injury provoked by MCA occlusion in spontaneously
hypertensive rats, although TNF-a toxicity was not related to
direct neuronal damage, and also demonstrated that anti–
TNF-a antibodies have a neuroprotective effect.75 Similarly,
the inhibition of TNF-a in mice with permanent MCA
occlusion leads to a smaller infarct volume.76 However, not
all studies agree about the deleterious role of TNF-a in brain
ischemia. When TNF-a is administered to mice 48 hours
before MCA occlusion, it induces a protective effect.77
Furthermore, the fact that mice lacking TNF-a receptors
show a larger infarct area after MCA occlusion than do
normal controls78 suggests that TNF-a may be beneficial in
the poststroke recovery phase. Finally, the specificity of
TNF-a expression after cerebral ischemia has been chal-
lenged by preliminary human data showing that TNF-a is
also expressed in the contralateral, nonischemic hemisphere.79
IL-6
IL-6 plays a central role in host defense as well as in acute
and chronic inflammatory activities80,81 and is expressed in
response to various forms of brain injury.81–85 In the rat, IL-6
mRNA is overexpressed 3 hours after permanent MCA
occlusion and reaches a peak at 12 hours; its expression
remains high for at least 24 hours.86
Higher IL-6 levels have been detected in the peripheral
blood of patients with acute cerebral ischemia than in control
subjects.52,87–89 Increased plasma and cerebrospinal fluid IL-6
levels are correlated with a larger infarct size on CT and
magnetic resonance imaging scans87,88 and with a poorer
clinical outcome,52 although it is not clear whether this simply
reflects an overproduction of IL-6 by larger lesions or a
directly damaging effect of IL-6 itself. In addition, it has not
yet been completely elucidated whether IL-6 exerts anti-
inflammatory or proinflammatory effects or both. Its anti-
inflammatory effect depends on the inhibition of IL-1 and
TNF-a production via a negative-feedback mechanism and
stimulation of the production of their circulating antagonists:
soluble TNF-a receptor and IL-1 receptor antagonist.80,90 Part
of the anti-inflammatory function of IL-6 can be attributed to
its ability to induce the release of corticotropin and corti-
sol91,92 and to promote the expression of acute-phase pro-
teins93,94 that have antiproteinase and oxygen-scavenger func-
tions.81 On the other hand, it has also been shown that IL-6
induces phospholipase A2 gene expression and as a conse-
quence, stimulates the production of leukotrienes, prostaglan-
dins, and platelet activating factor,95 all of which are involved
in ischemic brain damage.96
TGF-b
TGF-b is a cytokine that is known to regulate and stimulate
cell proliferation and differentiation and to play a central role
in tissue repair mechanisms.97 In rats exposed to 10 minutes
of global cerebral ischemia, increased expression of TGF-b
mRNA is seen after 6 hours throughout the brain; this
expression increases further at day 2 and subsides thereafter.98
One recent human autopsy study has found TGF-b mRNA
overexpression in ischemic tissue in comparison with sam-
ples taken from the contralateral, nonischemic side.99 The
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highest expression of TGF-b mRNA was detected in the
tissue surrounding the infarction (the penumbra zone).99 A
so-far-unexplained finding is that serum TGF-b levels are
lower in acute stroke patients than in control subjects, perhaps
owing to an accumulation of this cytokine in the ischemic
tissue.89
Preliminary results indicate that TGF-b may play a pro-
tective role in brain ischemia.100–104 Some of the proposed
reasons for this beneficial effect include (1) reduced neutro-
phil adherence to endothelial cells105; (2) suppression of the
release of potentially harmful oxygen- and nitrogen-derived
products by macrophages106,107; (3) the promotion of angio-
genesis in the penumbra area99; and (4) a reduction in the
expression and efficacy of other cytokines, such as TNF-
a,108,109 possibly by blocking p38 kinase and the consequent
inhibition of the TNF-a transduction mechanism.110
IFN-g
IFN-g is a protein produced by activated CD41 and CD81 T
cells and, to a lesser degree, by natural killer cells.111 IFN-g is not
produced by central nervous system cells, and its release at this
level is possible only when a breakdown of the blood-brain
barrier allows infiltration of lymphocytes into the brain paren-
chyma. Although the role of IFN-g (and of all the IFNs) in brain
ischemia has not been specifically addressed, blood-brain barrier
damage and leukocyte penetration are among the first conse-
quences of ischemic cerebral insults. Among many different
functions, IFN-g induces the expression of a variety of cytokines
by stimulating p38 kinase110 and of class II major histocompat-
ibility complex. Major histocompatibility complex is essential
for macrophages to recognize antigen, and thus, IFN-g could
play a crucial role in the development of brain necrosis after an
ischemic insult. Another possible role of IFN-g in cerebral
ischemia is the production of NO, with a consequent cytotoxic
effect on brain cells; in vitro, IFN-g stimulates the production of
interferon regulatory factor-1, which induces NO synthase
mRNA expression.112
Cell Adhesion Molecules in Cerebral Ischemia
Cell-Cell Adhesion
The adhesion of leukocytes to the endothelial surface and
their subsequent migration from the microvessels into the
brain parenchyma is mediated by a variety of molecules
located on the surface of both leukocytes and endothelial
cells. Adhesion molecules are conventionally divided into
four main families, each of which has a different function:
integrins, the immunoglobulin superfamily, cadherins, and
selectins.113 Under normal conditions, there is little or no
cell-surface expression of adhesion molecules114; their expres-
sion is induced by various inflammatory processes, such as
cerebral ischemia, with the upregulation mediated by cyto-
kines. Among the most studied adhesion molecules are
ICAM-1 (immunoglobulin superfamily), which is located on
the endothelial surface, and its leukocyte counterpart, integrin
CD11/CD18; many others are currently under investigation.
A number of animal studies have documented the upregula-
tion of endothelial-leukocyte adhesion molecule 1 (also
called E-selectin) in the microvessels,115–117 ICAM-1,118–122
and P-selectin118 after focal cerebral ischemia in rodents and
in nonhuman primates.
The possible relevance of adhesion molecules to the
pathogenesis of ischemic brain damage has recently been
corroborated by two studies demonstrating that, in compari-
son with normal controls, mice belonging to an ICAM-1–
deficient strain show a marked reduction in cerebral infarc-
tion size after transient MCA occlusion.35,123 As reviewed by
Feuerstein et al,74 cytokines can also induce the in vitro
expression of adhesion molecules in astrocytes, oligodendro-
cytes, and microglia. It is postulated that the presence of
adhesion molecules on the surface of glial cells may facilitate
the postischemic migration of leukocytes through the brain
parenchyma.74
One observation with potential clinical relevance is that the
expression of adhesion molecules caused by administration of
IL-1, TNF-a, and IFN-g is higher in endothelial cell cultures
from spontaneously hypertensive rats than in those derived
from normotensive rats.124 This finding suggests that ischemic
injuries of comparable severity may lead to more severe
consequences in hypertensive individuals.
Upregulation of adhesion molecules has been documented
in human stroke patients. In a preliminary study, leukocytes
from patients suffering an ischemic stroke or transient ische-
mic attack showed increased CD11a expression within 72
hours of the onset of symptoms in comparison with control
subjects matched for age and risk factors.125 Sobel et al126
detected increased ICAM-1 expression on the surface of
vessels from cerebral cortical infarcts in four patients. Soluble
isoforms of adhesion molecules, which are believed to be
shed from the surfaces of activated cells, can be quantified in
serum: in comparison with normal control subjects, patients
with acute stroke showed an initial increase in serum endo-
thelial-leukocyte adhesion molecule-1 levels (up to 24 hours
after stroke) and persistently increased levels of vascular cell
adhesion molecule-1 (up to 5 days).127 This temporal pattern
is in line with the current view that selectins, such as
endothelial-leukocyte adhesion molecule-1, mediate the ini-
tial low-affinity interaction between leukocytes and endothe-
lial cells and promote the margination and rolling of leuko-
cytes in the blood stream; subsequently, it is vascular cell
adhesion molecule-1 (immunoglobulin superfamily) that
causes the tight leukocyte-endothelial attachment and
transendothelial migration.
When evaluating the levels of adhesion molecules in
patients with cerebrovascular diseases, consideration should
be given to the possible confounding effect of risk factors for
atherosclerosis, a condition involving chronic inflammatory
endothelial activation.128 In acute ischemic stroke patients,
serum ICAM-1 levels have been found to be lower than129 or
the same as127 those of asymptomatic control subjects
matched for age, sex, and a number of vascular risk factors.
It can also be hypothesized that because of the long period (up
to 72 hours) for enrolling patients, in one of these two
studies,129 the theoretical initial peak serum level of adhesion
molecules could no longer be detected after they had bound to
leukocytes and endothelial cells.
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Cell-Matrix Adhesion
Another group of adhesion molecules is involved in cell-
matrix interaction. Integrins, the most widely studied adhe-
sion molecules of this group, are heterodimeric membrane
glycoproteins formed by the combination of an a- and a
b-subunit with an intracellular and an extracellular domain.113
At the basal membrane level, integrins connect endothelial
cells to extracellular components, such as laminin and colla-
gen. In the brain, endothelial cells, astrocytes, and the basal
membrane contribute to form the blood-brain barrier, and
their interconnection is mediated by integrins. Damage to
these molecules may therefore lead to severe damage of the
blood-brain barrier. Wagner et al130 have demonstrated that
integrin a6b4, that under physiological conditions mediates
the interaction between astrocytes and extracellular matrix, is
rapidly damaged during focal cerebral ischemia/reperfusion.
Other integrins play an important role in inflammatory
neoangiogenesis, wound repair, and ontogenesis and may
therefore be important for tissue repair after an ischemic
insult. Among these, integrin avb3, a receptor for molecules
sharing the common arginine-glycine–aspartic acid (RGD)
sequence (eg, vitronectin, fibrinogen, fibronectin, and lami-
nin), is expressed in basal ganglia microvessels in a nonhu-
man primate model of ischemia/reperfusion as early as 2
hours after MCA occlusion.131 The binding of ligand to
integrins modifies the conformation of their intracellular
domain so as to interfere with the cytoskeleton alignment,
modify cellular structure, and confer on the cell the ability to
migrate. Through these mechanisms, avb3 might play a role
during the first stages of vascular reorganization after cere-
bral ischemia.
Chemokines in Cerebral Ischemia
As IL-1b and TNF-a play a major role in promoting adhesion
between endothelial cells and leukocytes, they are poor
attractants for polymorphonuclear leukocytes and monocytes;
other chemoattractant cytokines (the so-called chemokines)
are believed to be specifically involved in guiding leukocytes
through the parenchyma and toward the ischemic area.
Chemokines are low-molecular-weight molecules charac-
terized by the presence, as a common structural pattern, of
four cysteine residues and are divided into two main families
(C-X-C and C-C chemokines) according to the presence or
absence of an amino acid between the residues of the two
most amino-proximal cysteines.36 This structural distinction
is reflected in vitro by a peculiar effect on different cell types:
C-X-C chemokines tend to attract neutrophils, whereas C-C
chemokines preferentially act on monocytes/macrophages.
Each chemokine family binds to specific receptors formed by
seven transmembrane domains that activate G proteins and
subsequently an intracellular kinase cascade.132 Chemokine
production and secretion are stimulated by a number of
compounds, such as bacterial lipopolysaccharide, IL-1a and
-1b, and TNF-a.36
Few chemokines have so far been studied in some detail in
experimental cerebral ischemia. Significant expression of
CINC mRNA has been detected in the ischemic areas of
spontaneously hypertensive rats 6 hours after permanent
MCA occlusion133; this expression peaks at 12 hours and
rapidly decreases at 24 hours. CINC has been shown to be
homologous to three “gro” human proteins and “KC” in the
mouse, and all of them are molecules acting predominantly as
neutrophil chemoattractants.134 In a model of rat transient
focal ischemia, the first detectable level of CINC in the brain
was observed 3 hours after reperfusion and preceded leuko-
cyte infiltration.135 In the sera of the same animals, a high
concentration of CINC was found 60 minutes after MCA
occlusion, with the peak concentration being reached 3 hours
after reperfusion; a reduction in levels was observed between
6 and 48 hours.135
The temporal expression of MCP-1 in brain ischemia follows
that of CINC. High levels of MCP-1 mRNA have been found in
the brains of rats with transient and permanent MCA occlusion
at 6 hours, with the highest expression occurring between 12
hours and 2 days136,137; increased MCP-1 expression was still
detectable 5 days after permanent MCA occlusion.136 The
observations that in vitro IL-1b and TNF-a induce MCP-1 gene
expression138 and that in vivo MCP-1 mRNA temporal expres-
sion follows that of IL-1b and TNF-a mRNA45,67 suggest that
IL-1b and TNF-a induce MCP-1 expression in cerebral ische-
mia. According to Gourmala et al,139 6 hours to 2 days after
MCA occlusion, MCP-1 mRNA is present in rat astrocytes
surrounding the ischemic tissue. After 4 days, MCP-1 mRNA is
found in macrophages and microglial cells in the infarcted tissue.
The mRNA of another member of the C-C chemokine
family, MIP-1a, has been found to be overexpressed in
cerebral ischemic areas.137 This chemokine attracts mono-
cytes and macrophages and modulates their activity in tissue
undergoing an inflammatory process. Kim et al137 found that
the temporal expression of MIP-1a parallels that of MCP-1
and that the distribution of MIP-1a–positive cells was similar
to that of activated astrocytes. MIP-1a infused into the
subarachnoid space of rabbits treated with Gram-negative
bacteria initially attracts neutrophils and subsequently mono-
cytes.140 If this sequence also holds true in cerebral ischemia,
this molecule could be in part responsible for the switch from
a leukocyte- to a macrophage-based inflammatory response.
The temporal profile of CINC, MCP-1, and MIP-1a expres-
sion is in line with that of leukocyte accumulation in the
ischemic brain parenchyma of nonhuman primates. In these
models, polymorphonuclear cells are detected 24 to 72 hours
after the onset of ischemia, followed at 7 to 16 days by
monocyte and macrophage infiltration.9,13
In vitro, smooth muscle cells stimulated by IFN and IL-1b
or TNF-a produce IFN-inducible protein-10, which is a
chemoattractant for macrophages and activated T lympho-
cytes.141 Inducible protein-10 mRNA expression has been
demonstrated in the rat after endothelial damage by balloon
angioplasty.141 Because endothelial damage occurs during
brain ischemia, it seems possible that this molecule could also
play a role in this latter pathological condition.
The number of discovered chemokines is continuously
growing, and so far, more than 20 members of this cytokine
family have been identified. It is likely that in the future, the
activity of other chemokines may be found to be increased
after cerebral ischemia and their function elucidated.
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Experimental Anti-Leukocyte Interventions
On the basis of the progress made in our understanding of
inflammatory-like mechanisms in cerebral ischemia, an in-
creasing number of molecules are currently being investi-
gated in animals for their possible effectiveness in human
acute stroke.
One group of studies has focused on therapeutic strategies
related to the role of proinflammatory cytokines. The intra-
ventricular and systemic administration of IL-1 receptor
antagonist into rats reduces the volume of infarction caused
by MCA occlusion54,59,62,64 or the ligation of one carotid artery
associated with hypoxia.61 This reduction in infarct size is
accompanied by a decreased number of leukocytes in the
ischemic hemisphere and improved neurological function.62
Similar results have been achieved by means of the topical
application of anti–IL-1b neutralizing antibody,53 zinc proto-
porphyrin,53,60,63 and fragments of lipocortin-1,58 all of which
act as IL-1 inhibitors. TGF-b administration has led to less
severe histological damage in a rabbit model of embolic
stroke100 as well as in rats subjected to permanent MCA
occlusion,101 transient global ischemia,104 and hypoxia-ische-
mia cerebral insult.103
A second group of studies has concentrated on molecules
that are capable of blocking the adhesion between endothelial
cells and leukocytes. The administration of anti–CD11b/
CD18 monoclonal antibodies at various times after reperfu-
sion reduces infarct volume in rats with MCA occlusion142,143
in a dose-dependent manner,144 although single administration
of the same drug 1 hour after permanent MCA occlusion led
to less striking effects.145 Treatment with antibodies against
ICAM-1 or integrin CD11b/CD18 is also capable of reducing
the number of apoptotic cells in the ischemic brain area.146
The use of anti–ICAM-1 antibodies reduces infarct volume
and the number of tissue polymorphonuclear leukocytes in
rats with transient MCA occlusion,147,148 but the treatment is
ineffective when administered to animals with permanent
occlusion.149 The same dichotomy between transient and
permanent ischemia has been shown in one model of spinal
cord ischemia.150 These observations suggest that drugs
blocking leukocyte-endothelial adhesion are effective only in
the presence of reperfusion.
Because monoclonal antibodies are immunogenic and
might have collateral effects in stroke patients, new nonim-
munogenic molecules are now being tested in animal models
with encouraging results.151,152 These are peptides or glyco-
proteins, which are produced by bacteria and which structur-
ally or functionally mimic cell adhesion molecules and inhibit
leukocyte function.
Conclusions
Leukocytes and Inflammatory Mediators in
Cerebral Ischemia
The studies reviewed in this article emphasize the possible
role of cytokines and cell adhesion molecules in the devel-
opment of cerebral damage caused by an ischemic insult.
Early overexpression of these inflammatory mediators pro-
motes the recruitment of leukocytes in the ischemic area and
represents a key mechanism for the evolution of tissue
damage. Leukocytes are in fact believed to have a deleterious
effect in brain ischemia. In the microvessels, they first adhere
to endothelial cells, interfering with local cerebral blood flow
and enhancing the ischemic insult. Subsequently, leukocytes
proceed through the endothelial lining and accumulate in the
ischemic area, where they release a number of toxic mole-
cules that contribute to the development of an infarction.
Relevance of Animal Models
Most of the evidence comes from animal studies; only
preliminary observations relating to humans are available. It
is plausible that our knowledge of the role of inflammation in
human stroke will considerably expand in the future, in terms
of both new molecules and a more precise definition of their
action, but it is likely that animal models will continue to
represent a fundamental source of information. The possibil-
ity that leukocyte alterations in experimental models may be
determined by the surgical procedures used to induce the
ischemic insult or by anesthesia has been refuted in a
nonhuman primate model.153 Moreover, the use of sham-
operated animals (ie, animals in which all of the phases of the
surgical procedure except artery occlusion are reproduced)
makes it possible to control for the influence of surgery and
anesthesia. Some of the substantial advantages of experimen-
tal models are the following: (1) The possibility of knowing
the exact time of onset of ischemia means that the temporal
pattern of the expression of the molecules under study can be
investigated; (2) Access to brain tissue for pathological
observation is simple; (3) New drugs can be tested. Never-
theless, it should be borne in mind that most of the conclu-
sions are based on rodent experiments because data from
nonhuman primate models (which are probably of greater
relevance to human disease) are still scarce.
Therapeutic Perspectives
Acute stroke therapy is probably destined to change over the
next few years. One of the crucial turning points will be
definition of the time interval during which the administration
of drugs is likely to be efficacious (therapeutic window),
which is not easy because of individual patient variability.
Most of the trials carried out so far suggest a very narrow (3
hours) therapeutic window, which in the case of thrombolytic
agents, is due more to the increased occurrence of hemor-
rhagic transformation than a lack of efficacy beyond this
limit. Animal and human studies have shown that the evolu-
tion of a brain infarct progresses over a longer period of
time,23,24,154,155 and so the reopening of an artery could also be
advantageous at a later time.
New drugs counteracting cytokine-mediated damage or
opposing leukocyte–endothelial cell adhesion are already
being investigated in animals with encouraging results. One
perspective for the use of drugs capable of interfering with
inflammation-related mechanisms is the possibility of widen-
ing the therapeutic window; in a rabbit model of embolic
stroke, administration of anti–ICAM-1 antibodies has been
shown to extend the time during which the thrombolytic
agent was effective in dissolving blood clots.156 The timing of
arrival of many stroke patients to the emergency depart-
ment157 seems compatible with potential drug interventions
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designed to interfere with inflammatory mediators and the
natural evolution of the ischemic lesion. The inflammatory
response of the cerebral parenchyma, with the above-dis-
cussed harmful implications, develops over days after the
onset of ischemia in the animal,20 and this is probably also
true in humans.12 Therefore, these therapeutic strategies could
theoretically be undertaken far beyond the strict time limit of
thrombolysis with some beneficial effects.
Possible future pharmacological treatments could be based
on the inhibition of proinflammatory mediators (perhaps IL-1
and TNF-a) or enhancement of the effect of others (IL-6 and
TGF-b). Some cytokines and chemokines, such as IFN-g and
MIP-1, seem to play a role in the passage from the first phase
of the inflammatory response, characterized by the presence
of polymorphonuclear cells, to the second, with monocyte
and macrophage invasion and the development of frank
necrosis. Blocking these molecules could prevent part of the
brain parenchyma from becoming necrotic. Interfering with
adhesion between leukocytes and endothelial cells represents
a second therapeutic option. On the other hand, attempts
could be made to potentiate the role of integrins that promote
cell remodeling and neovascularization. Other targets for a
possible pharmacological approach are the specific transduc-
tion pathway signals (eg, intracytoplasmic kinases) that are
critical for cytokine production and their effects.
Caveats and Limitations
An understanding of the role of leukocytes and the mediators
of inflammation in cerebral ischemia may have a very great
impact on therapy, but a few notes of caution should be
outlined. Although it currently seems that some cytokines,
such as IL-1, have a detrimental effect and that others, such
as TGF-b and IL-6, might be protective in some way, the
precise effect of each mediator is still not completely known.
Moreover, some data exist challenging the view that leuko-
cytes are active in favoring the progression from cerebral
ischemia to necrosis.158–160
The expectations aroused by animal studies have been
somewhat dampened by the results of the first human trial
using an anti–ICAM-1 murine monoclonal antibody (Enli-
momab, Boehringer Ingelheim). In this double-blind, place-
bo-controlled trial, 625 patients with acute ischemic stroke
were randomized within the first 6 hours of symptom onset to
receive either anti–ICAM-1 antibodies (160 mg IV the first
day, followed by 40 mg/d for 2 to 5 days after onset) or
placebo.161 The 90-day outcome as measured by the modified
Rankin Scale showed an improvement in 33% of the patients
on placebo versus 27% of those receiving active treatment.
Side effects (mainly fever, infections, and pneumonia) were
recorded in 44% of the Enlimomab and 30% of the placebo
patients; serious adverse effects (stroke progression, brain
edema, and hemorrhagic transformation of the infarction)
were observed in 22% of the Enlimomab versus 16% of the
placebo patients; both of these differences were statistically
significant. Moreover, the occurrence of cases of aseptic
meningitis in the Enlimomab group underlines the limitations
due to the immunogenic effect of this drug.
Is There Still a Role for Anti-Leukocytes
Interventions in Human Stroke?
However, before setting aside anti–ICAM-1 antibodies as
another ineffective drug in acute ischemic stroke, the prelim-
inary results of the Enlimomab study should be critically
considered. First of all, anti-leukocyte interventions appear to
be particularly effective against reperfusion injury. Anti–
ICAM-1 antibodies have been tested and proved efficacious
in models of transient146–148,150 but not permanent149 focal
ischemia, presumably the condition of most of the patients
enrolled in the Enlimomab trial. As shown by Bowes et al,156
the use of anti–ICAM-1 might be beneficial only in combi-
nation with thrombolysis. Second, the time and route of drug
administration could be crucial: in none of the reviewed
animal studies was the first dose of anti–ICAM-1 antibodies
delayed beyond 1 hour after reperfusion, and systemic ad-
ministration could lead to a reduction in host defenses and a
predisposition to infections. Finally, given the increased
frequency of fever and aseptic meningitis among the treated
patients, the immunogenic role of anti–ICAM-1 antibodies
needs to be weighed very carefully.
In the light of the above considerations, among others, a
multitherapeutic approach for ischemic stroke can be fore-
seen.162 The testing of new anti-leukocyte drugs in humans
probably requires further elucidation of the pathophysiolog-
ical role that these cells play during cerebral ischemia. At
present, it would be dangerous to simply dismiss those drugs
that may prove to be efficacious in different target
populations.
Acknowledgment
The authors thank Thomas DeGraba, MD (National Institute of
Neurological Disorders and Stroke, Stroke Branch, National Insti-
tutes of Health, Bethesda, Md) for his helpful revision of
the manuscript.
References
1. Riggs JE. Tissue-type plasminogen activator should not be used in acute
ischemic stroke. Arch Neurol. 1996;53:1306–1308.
2. Furlan AJ, Kanoti G. When is thrombolysis justified in patients with
acute ischemic stroke? A bioethical perspective. Stroke. 1997;28:
214–218.
3. The National Institute of Neurological Disorders and Stroke rt-PA
Stroke Study Group. Tissue plasminogen activator for acute ischemic
stroke. N Engl J Med. 1995;333:1581–1587.
4. Wardlaw JM, Warlow CP, Counsell C. Systematic review of evidence
on thrombolytic therapy for acute ischaemic stroke. Lancet. 1997;350:
607–614.
5. Syrjanen J, Valtonen VV, Iivanainen M, Kaste M, Huttunen JK. Pre-
ceding infection as an important risk factor for ischaemic brain
infarction in young and middle aged patients. BMJ. 1988;296:
1156–1160.
6. Grau AJ, Buggle F, Heindl S, Steichen-Wiehn C, Banerjee T, Mainwald
M, Rohlfs M, Suhr H, Fiehn W, Becher H, Hacke W. Recent infection
as a risk factor for cerebrovascular ischemia. Stroke. 1995;26:373–379.
7. Macko RF, Ameriso SF, Barndt R, Clough W, Weiner JM, Fisher M.
Precipitants of brain infarction: roles of preceding infection/
inflammation and recent psychological stress. Stroke. 1996;27:
1999–2004.
8. Bova IY, Bornstein NM, Korczyn AD. Acute infection as a risk factor
for ischemic stroke. Stroke. 1996;27:2204–2206.
9. Kochanek PM, Hallenbeck JM. Polymorphonuclear leukocytes and
monocytes/macrophages in the pathogenesis of cerebral ischemia and
stroke. Stroke. 1992;23:1367–1379.
10. So¨rna¨s R, Ostlund H, Muller R. Cerebrospinal fluid cytology after
stroke. Arch Neurol. 1972;26:489–501.
Pantoni et al April 1998 509
 by guest on February 27, 2018
http://atvb.ahajournals.org/
D
ow
nloaded from
 
11. Akopov SE, Simonian NA, Grigorian GS. Dynamics of poly-
morphonuclear leukocyte accumulation in acute cerebral infarction and
their correlation with brain tissue damage. Stroke. 1996;27:1739–1743.
12. Chuaqui R, Tapia J. Histologic assessment of the age of recent brain
infarcts in man. J Neuropathol Exp Neurol. 1993;52:481–489.
13. Garcia JH, Kamijyo Y. Cerebral infarction: evolution of histopatho-
logical changes after occlusion of a middle cerebral artery in primates.
J Neuropathol Exp Neurol. 1974;33:408–421.
14. Hallenbeck JM, Dutka AL, Tanishima T, Kochanek PM, Kumaroo KK,
Thompson CB, Obrenovitch TP, Contreras TJ. Polymorphonuclear leu-
kocyte accumulation in brain regions with low blood flow during the
early postischemic period. Stroke. 1986;17:246–253.
15. Barone FC, Hillegas LM, Price WJ, White RF, Lee EV, Feuerstein GZ,
Sarau HM, Clark RK, Griswold DE. Polymorphonuclear leukocyte infil-
tration into cerebral focal ischemic tissue: myeloperoxidase activity
assay and histologic verification. J Neurosci Res. 1991;29:336–345.
16. del Zoppo GJ, Schmidt-Schonbein GW, Mori E, Copeland BR, Chang
CM. Polymorphonuclear leukocytes occlude capillaries following
middle cerebral artery occlusion and reperfusion in baboons. Stroke.
1991;22:1276–1283.
17. Barone FC, Schmidt DB, Hillegas LM, Price WJ, White RF, Feuerstein
GZ, Clark RK, Lee EV, Griswold DE, Sarau HM. Reperfusion increases
neutrophils and leukotriene B4 receptor binding in rat focal ischemia.
Stroke. 1992;23:1337–1348.
18. Dereski MO, Chopp M, Knight RA, Chen H, Garcia JH. Focal cerebral
ischemia in the rat: temporal profile of neutrophil responses. Neurosci
Res Commun. 1992;11:179–186.
19. Clark RK, Lee EV, Fish CJ, White RF, Price WJ, Jonak ZL, Feuerstein
GZ, Barone C. Development of tissue damage, inflammation and reso-
lution following stroke: an immunohistochemical and quantitative plani-
metric study. Brain Res Bull. 1993;31:565–572.
20. Clark RK, Lee EV, White RF, Jonak ZL, Feuerstein GZ, Barone FC.
Reperfusion following focal stroke hastens inflammation and resolution
of ischemic injury. Brain Res Bull. 1994;35:387–392.
21. Zhang R-L, Chopp M, Chen H, Garcia JH. Temporal profile of ischemic
tissue damage, neutrophil response, and vascular plugging following
permanent and transient (2H) middle cerebral artery occlusion in the rat.
J Neurol Sci. 1994;125:3–10.
22. Garcia JH, Liu K-F, Yoshida Y, Lian J, Chen S, del Zoppo GJ. Influx of
leukocytes and platelets in an evolving brain infarct (Wistar rat). Am J
Pathol. 1994;144:188–199.
23. Garcia JH, Yoshida Y, Chen H, Li Y, Zhang ZG, Lian J, Chen S, Chopp
M. Progression from ischemic injury to infarct following middle
cerebral artery occlusion in the rat. Am J Pathol. 1993;142:623–635.
24. Garcia JH, Liu K-F, Ho K-L. Neuronal necrosis after middle cerebral
artery occlusion in Wistar rats progresses at different time intervals in
the caudoputamen and the cortex. Stroke. 1995;26:636–643.
25. Ames A, Wright LW, Kowade M, Thurston JM, Majors G. Cerebral
ischemia, II: the no-reflow phenomenon. Am J Pathol. 1968;52:
437–453.
26. Schmid-Scho¨nbein GW, Usami S, Skalak R, Chien S. The interaction of
leukocytes and erythrocytes in capillary and postcapillary. Microvasc
Res. 1980;19:45–70.
27. Sutton DW, Schmid-Scho¨nbein GW. Elevation of organ resistance due
to leukocyte perfusion. Am J Physiol. 1992;262:H1648–H1650.
28. Ha¨rtl R, Schu¨rer L, Schmid-Scho¨nbein GW, del Zoppo G. Experimental
antileukocyte interventions in cerebral ischemia. J Cereb Blood Flow
Metab. 1996;16:1108–1119.
29. Hamann GF, del Zoppo GJ. Leukocyte involvement in vasomotor reac-
tivity of the cerebral vasculature. Stroke. 1994;25:2117–2119.
30. Hamann GF, Okada Y, Fitridge R, del Zoppo GJ. Microvascular basal
lamina antigens disappear during cerebral ischemia and reperfusion.
Stroke. 1995;26:2120–2126.
31. Hamann GF, Okada Y, del Zoppo GJ. Hemorrhagic transformation and
microvascular integrity during focal cerebral ischemia/reperfusion.
J Cereb Blood Flow Metab. 1996;16:1373–1378.
32. Bednar MM, Raymond S, McAuliffe T, Lodge PA, Gross CG. The role
of neutrophils and platelets in a rabbit model of thromboembolic stroke.
Stroke. 1991;22:44–50.
33. Chen H, Chopp M, Bodzin G. Neutropenia reduces the volume of
cerebral infarct after transient middle cerebral occlusion in the rat.
Neurosci Res Commun. 1992;11:93–99.
34. Matsuo Y, Onodera H, Shiga Y, Nakamura M, Ninomiya M, Kihara T,
Kogure K. Correlation between myeloperoxidase-quantified neutrophil
accumulation and ischemic brain injury in the rat: effects of neutrophil
depletion. Stroke. 1994;25:1469–1475.
35. Connolly ES Jr, Winfree CJ, Springer TA, Naka Y, Liao H, Yan SD,
Stern DM, Solomon RA, Gutierrez-Ramos J-C, Pinsky DJ. Cerebral
protection in homozygous null ICAM-1 mice after middle cerebral
artery occlusion: role of neutrophil adhesion in the pathogenesis of
stroke. J Clin Invest. 1996;97:209–216.
36. Furie MB, Randolph GJ. Chemokines and tissue injury. Am J Pathol.
1995;146:1287–1301.
37. Howard MC, Miyajima A, Coffmann R. T-cell-derived cytokines and
their receptors. In: We P, ed. Fundamental Immunology. 3rd ed. New
York, NY: Raven Press Ltd; 1993:763–800.
38. Fontana A, Kristensein F, Dubi R, Gemsa D, Weber E. Production of
prostaglandin E and interleukin-1 like factor by cultured astrocytes and
C6 glioma cells. J Immunol. 1982;129:2413–2418.
39. Giulian D, Baker TJ, Shih LN, Lachman LB. Interleukin-1 of central
nervous system is produced by ameboid microglia. J Exp Med. 1986;
164:594–604.
40. Lechan RM, Clark TBD, Cannon JG, Shaw AR, Dinarello CA, Reichlin
S. Immunoreactive IL-1b localization in the rat forebrain. Brain Res.
1990;514:135–140.
41. Tomimoto H, Akiguchi I, Wakita H, Kinoshita A, Ikemoto A, Nakamura
S, Kimura J. Glial expression of cytokines in the brains of cerebro-
vascular disease patients. Acta Neuropathol (Berl). 1996;92:281–287.
42. Bevilacqua MP, Pober JS, Majeau GR, Cotran RS, Gimbrone MA Jr.
Interleukin 1 (IL-1) induces biosynthesis and cell surface expression of
procoagulant activity in human vascular endothelial cells. J Exp Med.
1984;160:618–623.
43. Conway EM, Bach R, Rosenberg RD, Konigsberg WH. Tumor necrosis
factor enhances expression of tissue factor mRNA in endothelial cells.
Thromb Res. 1989;53:231–241.
44. Nawroth PP, Handley DA, Esmon CT, Stern DM. Interleukin-1 induces
endothelial cell procoagulant while suppressing cell-surface antico-
agulant activity. Proc Natl Acad Sci U S A. 1986;83:3460–3464.
45. Liu T, McDonnell PC, Young PR, White RF, Siren AL, Hallenbeck JM,
Barone FC, Feuerstein GZ. Interleukin-1b mRNA expression in ische-
mic rat cortex. Stroke. 1993;24:1746–1751.
46. Buttini M, Sauter A, Boddeke HWGM. Induction of interleukin-1b
mRNA after focal cerebral ischemia in the rat. Mol Brain Res. 1994;
23:126–134.
47. Minami M, Kuraishi Y, Yabuuchi K, Yamazaki A, Satoh M. Induction
of interleukin-1b mRNA in rat brain after transient forebrain ischemia.
J Neurochem. 1992;58:390–392.
48. Wiessner C, Gehrmann J, Lindholm D, Topper R, Kreutzberg GW,
Hossmann KA. Expression of transforming growth factor-beta 1 and
interleukin-1 beta mRNA in rat brain following transient forebrain
ischemia. Acta Neuropathol (Berl). 1993;86:439–446.
49. Yabuuchi K, Minami M, Katsumata S, Yamazaki A, Satoh M. An in situ
hybridization study on interleukin-1b mRNA induced by transient
forebrain ischemia in the rat brain. Mol Brain Res. 1994;26:135–142.
50. Yoshimoto T, Houkin K, Tada M, Abe H. Induction of cytokines,
chemokines, and adhesion molecule mRNA in a rat forebrain reper-
fusion model. Acta Neuropathol (Berl). 1997;93:154–158.
51. Szaflarski J, Burtrum D, Silverstein FS. Cerebral hypoxia-ischemia
stimulates cytokine gene expression in perinatal rats. Stroke. 1995;26:
1093–1100.
52. Fassbender K, Rossol S, Kammer T, Daffertshofer M, Wirth S, Dollman
M, Hennerici M. Proinflammatory cytokines in serum of patients with
acute cerebral ischemia: kinetics of secretion and relation to the extent
of brain damage and outcome disease. J Neurol Sci. 1994;122:135–139.
53. Yamasaki Y, Matsuura N, Shozuhara H, Onodera H, Itoyama Y, Kogure
K. Interleukin-1 as a pathogenetic mediator of ischemic brain damage in
rats. Stroke. 1995;26:676–681.
54. Loddick SA, Rothwell NJ. Neuroprotective effects of human recom-
binant interleukin-1 receptor antagonist in focal cerebral ischaemia in
the rat. J Cereb Blood Flow Metab. 1996;16:932–940.
55. Wang X, Barone FC, Aiyar NV, Feuerstein GZ. Interleukin-1 receptor
antagonist gene expression after focal stroke in rats. Stroke. 1997;28:
155–162.
56. Dinarello CA. Interleukin-1 and interleukin-1 antagonism. Blood. 1991;
77:1627–1652.
57. Muegge K, Williams TM, Kant J, Karin M, Chiu R, Schmidt A,
Siebenlist U, Young HA, Durum SK. Interleukin-1 costimulatory
activity on the interleukin-2 promoter via AP-1. Science. 1989;246:
249–251.
510 Cytokines and Adhesion Molecules in Cerebral Ischemia
 by guest on February 27, 2018
http://atvb.ahajournals.org/
D
ow
nloaded from
 
58. Relton JK, Strijbos PJLM, O’Shaughnessy CT, Carey F, Forder RA,
Tilders FJH, Rothwell NJ. Lipocortin-1 is an endogenous inhibitor of
ischemic damage in the rat brain. J Exp Med. 1991;174:305–310.
59. Relton JK, Rothwell NJ. Interleukin-1 receptor antagonist inhibits
ischaemic and excitotoxic neuronal damage in the rat. Brain Res Bull.
1992;29:243–246.
60. Yamasaki Y, Suzuki T, Yamaya H, Matsuura N, Onodera H, Kogure K.
Possible involvement of interleukin-1 in ischemic brain edema for-
mation. Neurosci Lett. 1992;142:45–47.
61. Martin D, Chinookoswong N, Miller G. The interleukin-1 receptor
antagonist (rhIL-1ra) protects against cerebral infarction in a rat model
of hypoxia-ischemia. Exp Neurol. 1994;130:362–367.
62. Garcia JH, Liu K-F, Relton JK. Interleukin-1 receptor antagonist
decreases the number of necrotic neurons in rats with middle cerebral
artery occlusion. Am J Pathol. 1995;147:1477–1486.
63. Kadoya C, Domino EF, Yang GY, Stern JD, Betz AL. Preischemic but
not postischemic zinc protoporphyrin treatment reduces infarct size and
edema accumulation after temporary focal cerebral ischemia in rats.
Stroke. 1995;26:1035–1038.
64. Relton JK, Martin D, Thompson RC, Russell DA. Peripheral adminis-
tration of interleukin-1 receptor antagonist inhibits brain damage after
focal cerebral ischemia in the rat. Exp Neurol. 1996;138:206–213.
65. Rothwell NJ, Relton JK. Involvement of interleukin-1 and lipocortin-1
in ischemic brain damage. Cerebrovasc Brain Metab Rev. 1993;5:
178–198.
66. Wang X, Yue TL, Barone FC, White RF, Gagnon RC, Feuerstein GZ.
Concomitant cortical expression of TNF-a and IL-1b mRNA follows
early response gene expression in transient focal ischemia. Mol Chem
Neuropathol. 1994;23:103–114.
67. Liu T, Clark RK, McDonnell PC, Young PR, White RF, Barone FC,
Feuerstein GZ. Tumor necrosis factor-a expression in ischemic neurons.
Stroke. 1994;25:1481–1488.
68. Elneihoum AM, Falke P, Axelsson L, Lundberg E, Lindga¨rde F,
Ohlsson K. Leukocyte activation detected by increased plasma levels of
inflammatory mediators in patients with ischemic cerebrovascular
diseases. Stroke. 1996;27:1734–1738.
69. Smith CA, Farrah T, Goodwin RG. The TNF receptor superfamily of
cellular and viral proteins: activation, costimulation, and death. Cell.
1994;76:959–962.
70. Kolesnick R, Golde DW. The sphingomyelin pathway in tumor necrosis
factor and interleukin-1 signaling. Cell. 1994;77:325–328.
71. Davis RJ. MAPKs: new JNK expands the group. Trends Biochem Sci.
1994;19:470–473.
72. Blumer KJ, Johnson GL. Diversity in function and regulation of MAP
kinase pathways. Trends Biochem Sci. 1994;19:236–240.
73. Heller RA, Konkre M. Tumor necrosis factor receptor-mediated sig-
naling pathways. J Cell Biol. 1994;126:5–9.
74. Feuerstein GZ, Liu T, Barone FC. Cytokines, inflammation, and brain
injury: role of tumor necrosis factor-a. Cerebrovasc Brain Metab Rev.
1994;6:341–360.
75. Barone FC, Arvin B, White RF, Miller A, Webb CL, Willette RN, Lysko
PG, Feuerstein GZ. Tumor necrosis factor-a: a mediator of focal ische-
mic brain injury. Stroke. 1997;28:1233–1244.
76. Nawashiro H, Martin D, Hallenbeck JM. Inhibition of tumor necrosis
factor and amelioration of brain infarction in mice. J Cereb Blood Flow
Metab. 1997;17:229–232.
77. Nawashiro H, Tasaki K, Ruetzler CA, Hallenbeck JM. TNF-a pre-
treatment induces protective effects against focal cerebral ischemia in
mice. J Cereb Blood Flow Metab. 1997;17:483–490.
78. Bruce AJ, Boling W, Kindy MS, Peshon J, Kraemer PJ, Carpenter MK,
Holtsberg FW, Mattson MP. Altered neuronal and microglial responses
to excitotoxic and ischemic brain injury in mice lacking TNF receptors.
Nat Med. 1996;2:788–794.
79. Vidman TR, Carpe´n O, Paetau A, Karjalainen-Lindsberg M-L,
Lindsberg PJ. Production of tumor necrosis factor-a (TNF-a) in
infarcted human brain. Stroke. 1997;28:255. Abstract.
80. Hirano T. The biology of interleukin-6. Chem Immunol. 1992;51:
153–180.
81. Akira S, Taga T, Kishimoto T. Interleukin-6 in biology and medicine.
Adv Immunol. 1993;54:1–78.
82. McClain C, Cohen D, Phillips R, Ott L, Young B. Increased plasma and
ventricular fluid interleukin-6 levels in patients with head injury. J Lab
Clin Med. 1991;118:225–231.
83. Woodroofe MN, Sarna GS, Wadhwa M, Hayes GM, Loughlin AJ,
Tinker A, Cuzner ML. Detection of interleukin-1 and interleukin-6 in
adult rat brain, following mechanical injury, by in vivo microdialysis:
evidence of a role for microglia in cytokine production. J Neuro-
immunol. 1991;33:227–236.
84. Yan HQ, Banos MA, Herregodts P, Hooghe R, Hooghe-Peters EL.
Expression of interleukin (IL)-1b, IL-6 and their respective receptors in
the normal rat brain after injury. Eur J Immunol. 1992;22:2963–2971.
85. Mathiesen T, Andersson B, Loftenus A, von Holst H. Increased
interleukin-6 levels in cerebrospinal fluid following subarachnoid hem-
orrhage. J Neurosurg. 1993;78:562–567.
86. Wang X, Yue TL, Young PR, Barone FC, Feuerstein GZ. Expression of
interleukin-6, c-fos, and zif268 mRNA in rat ischemic cortex. J Cereb
Blood Flow Metab. 1995;15:166–171.
87. Beamer NB, Coull BM, Clark WM, Hazel JS, Silberger JR.
Interleukin-6 and interleukin-1 receptor antagonist in acute stroke. Ann
Neurol. 1995;37:800–805.
88. Tarkowski E, Rosengren L, Blomstrand C, Wikkelso¨ C, Jensen C,
Ekholm S, Tarkowski A. Early intrathecal production of interleukin-6
predicts the size of brain lesion in stroke. Stroke. 1995;26:1393–1398.
89. Kim JS, Yoon SS, Kim YH, Ryu JS. Serial measurement of
interleukin-6, transforming growth factor-b, and S-100 protein in
patients with acute stroke. Stroke. 1996;27:1553–1557.
90. Tilg H, Trehu E, Atkins MB, Dinarello CA, Mier JW. Interleukin-6
(IL-6) as an anti-inflammatory cytokine: induction of circulating IL-1
receptor antagonist and soluble tumor necrosis factor receptor p55.
Blood. 1994;83:113–118.
91. Salas MA, Evans SW, Levell MJ, Whicher JT. Interleukin-6 and ACTH
act synergistically to stimulate the release of corticosterone from adrenal
gland cells. Clin Exp Immunol. 1990;79:470–473.
92. Jones TH. Interleukin-6 an endocrine cytokine. Clin Endocrinol (Oxf).
1994;40:703–713.
93. Geiger T, Andus T, Klapproth J, Hirano T, Kishimoto T, Heinrich PC.
Induction of rat acute-phase proteins by interleukin-6 in vivo. Eur
J Immunol. 1988;18:717–721.
94. Heinrich PC, Castell JV, Andus T. Interleukin-6 and the acute phase
response. Biochem J. 1990;265:621–636.
95. Crowl RM, Stoller TJ, Conroy RR, Stoner CR. Induction of phospho-
lipase A2 gene expression in human hepatoma cells by mediators of the
acute phase response. J Biol Chem. 1991;266:2647–2651.
96. Raichle ME. The pathophysiology of brain ischemia. Ann Neurol. 1983;
13:2–10.
97. Wahl SM. Transforming growth factor beta (TGF-b) in inflammation: a
cause and a cure. J Clin Immunol. 1992;12:61–74.
98. Lehrmann E, Kiefer R, Finsen B, Diemer NH, Zimmer J, Hartung HP.
Cytokines in cerebral ischemia: expression of transforming growth
factor beta-1 (TGF-b1) mRNA in the postischemic adult rat hip-
pocampus. Exp Neurol. 1995;131:114–123.
99. Krupinski J, Kumar P, Kumar S, Path FRC, Kaluza J. Increased
expression of TGF-b1 in brain tissue after ischemic stroke in humans.
Stroke. 1996;27:852–857.
100. Gross CE, Bednar MM, Howard DB, Sporn MB. Transforming growth
factor-b1 reduces infarct size after experimental cerebral ischemia in a
rabbit model. Stroke. 1993;24:558–562.
101. Prehn JH, Backhauss C, Krieglstein J. Transforming growth factor-beta
1 prevents glutamate neurotoxicity in rat neocortical cultures and
protects mouse neocortex from ischemic injury in vivo. J Cereb Blood
Flow Metab. 1993;13:521–525.
102. Gross CE, Howard DB, Dooley RH, Raymond SJ, Fuller S, Bednar MM.
TGF-beta 1 post-treatment in a rabbit model of cerebral ischaemia.
Neurol Res. 1994;16:465–470.
103. McNeill H, Williams C, Guan J, Dragunow M, Lawlor P, Sirimanne E,
Nikolics K, Gluckman P. Neuronal rescue with transforming growth
factor-beta 1 after hypoxic-ischaemic brain injury. Neuroreport. 1994;
14:901–904.
104. Henrich-Noack P, Prehn JHM, Krieglstein J. TGF-b1 protects hip-
pocampal neurons against degeneration caused by transient global is-
chemia: dose-response relationship and potential neuroprotective mech-
anisms. Stroke. 1996;27:1609–1615.
105. Gamble JR, Vadas MA. Endothelial adhesiveness for blood neutrophils
is inhibited by transforming growth factor-b. Science. 1988;242:97–99.
106. Tsunawaki S, Sporn M, Ding A Nathan C. Deactivation of macrophages
by transforming growth factor-b. Nature. 1988;334:260–262.
107. Ding A, Nathan CF, Graycar J, Derynck R, Stuehr DJ, Srimal S.
Macrophage deactivating factor and transforming growth factors-b1,
-b2, -b3 inhibit induction of macrophage nitrogen oxide synthesis by
IFN-g1. J Immunol. 1990;145:940–944.
Pantoni et al April 1998 511
 by guest on February 27, 2018
http://atvb.ahajournals.org/
D
ow
nloaded from
 
108. Lieberman AP, Pitha PM, Shin HS, Shin ML. Production of tumor
necrosis factor and other cytokines by astrocytes stimulated with lipo-
polysaccharide or a neurotropic virus. Proc Natl Acad Sci U S A. 1989;
86:6348–6352.
109. Lefer AM, Tsao P, Aoki N, Palladino MA Jr. Mediation of cardiopro-
tection by transforming growth factor-b. Science. 1990;249:61–64.
110. Rose DM, Winston BW, Chan ED, Riches DWH, Henson PM.
Interferon-g and transforming growth factor-b modulate the activation
of mitogen-activated protein kinases and tumor necrosis factor-a pro-
duction induced by Fcg-receptor stimulation in murine macrophages.
Biochem Biophys Res Commun. 1997;238:256–260.
111. Ijzermans JNM, Marquet RL. Interferon-gamma: a review. Immuno-
biology. 1989;179:456–473.
112. Kamijo R, Harada H, Matsuyama T, Bosland M, Gerecitano J, Shapiro
D, Le J, Koh SI, Kimura T, Green SJ, Mak TW, Taniguchi T, Vilcek J.
Requirement for transcription factor IRF-1 in NO synthase induction in
macrophages. Science. 1994;263:1612–1615.
113. Frenette PS, Wagner DD. Adhesion molecules, part I. N Engl J Med.
1996;334:1526–1529.
114. Osborn L. Leukocyte adhesion to endothelium in inflammation. Cell.
1990;62:3–6.
115. Wang X, Yue TL, Barone FC, Feuerstein GZ. Demonstration of
increased endothelial-leukocyte adhesion molecule-1 mRNA expression
in rat ischemic cortex. Stroke. 1995;26:1665–1669.
116. Haring H-P, Berg EL, Tsurushita N, Tagaya M, del Zoppo GJ. E-selectin
appears in nonischemic tissue during experimental focal cerebral ische-
mia. Stroke. 1996;27:1386–1392.
117. Zhang RL, Chopp M, Zhang ZG, Phillips ML, Rosenbloom CL, Cruz R,
Manning A. E-selectin on focal cerebral ischemia and reperfusion in the
rat. J Cereb Blood Flow Metab. 1996;16:1126–1136.
118. Okada Y, Copeland BR, Mori E, Tung MM, Thomas WS, del Zoppo GJ.
P-selectin and intercellular adhesion molecule-1 expression after focal
brain ischemia and reperfusion. Stroke. 1994;25:202–211.
119. Wang X, Siren A-L, Liu Y, Yue T-L, Barone FC, Feuerstein GZ.
Upregulation of intercellular adhesion molecule 1 (ICAM-1) on brain
microvascular endothelial cells in rat ischemic cortex. Mol Brain Res.
1994;26:61–68.
120. Zhang R-L, Chopp M, Zaloga C, Zhang ZG, Jiang N, Gautam SC, Tang
WX, Tsang W, Anderson DC, Manning AM. The temporal profiles of
ICAM-1 protein and mRNA expression after transient MCA occlusion
in the rat. Brain Res. 1995;682:182–188.
121. Jander S, Kraemer M, Schroeter M, Witte OW, Stoll G. Lymphocytic
infiltration and expression of intercellular adhesion molecule-1 in pho-
tochemically induced ischemia of the rat cortex. J Cereb Blood Flow
Metab. 1995;15:42–51.
122. Kato H, Kogure K, Liu X-H, Araki T, Itoyama Y. Progressive
expression of immunomolecules on activated microglia and invading
leukocytes following focal cerebral ischemia in the rat. Brain Res.
1996;734:203–212.
123. Soriano SG, Lipton SA, Wang YF, Xiao M, Springer TA,
Gutierrez-Ramos J-C, Hickey PR. Intercellular adhesion molecule-1
deficient mice are less susceptible to cerebral ischemia-reperfusion
injury. Ann Neurol. 1996;39:618–624.
124. McCarron RM, Wang L, Siren AL, Spatz M, Hallenbeck JM. Adhesion
molecules on normotensive and hypertensive rat brain endothelial cells.
Proc Soc Exp Biol Med. 1994;205:257–262.
125. Kim JS, Chopp M, Chen H, Levine SR, Carey JL, Welch KMA.
Adhesive glycoproteins CD11a and CD18 are upregulated in the leu-
kocytes from patients with ischemic stroke and transient ischemic
attacks. J Neurol Sci. 1995;128:45–50.
126. Sobel RA, Mitchell ME, Fronden G. Intercellular adhesion molecule-1
(ICAM-1) in cellular immune reactions in the human central nervous
system. Am J Pathol. 1990;136:1309–1316.
127. Fassbender K, Mo¨ssner R, Motsch L, Kischka U, Grau A, Hennerici M.
Circulating selectin- and immunoglobulin-type adhesion molecules in
acute ischemic stroke. Stroke. 1995;26:1361–1364.
128. Davies MJ, Gordon JL, Gearing AJ, Pigott R, Woolf N, Katz D,
Kyriakopoulos A. The expression of adhesion molecules ICAM-1,
VCAM-1, PECAM, and E-selectin in human atherosclerosis. J Pathol.
1993;171:223–229.
129. Clark WM, Coull BM, Briley DP, Mainolfi E, Rothlein R. Circulating
intercellular adhesion molecule-1 levels and neutrophil adhesion in
stroke. J Neuroimmunol. 1993;44:123–126.
130. Wagner S, Tagaya M, Koziol JA, Quaranta V, del Zoppo GJ. Rapid
disruption of an astrocyte interaction with the extracellular matrix
mediated by integrin a6b4 during focal cerebral ischemia/reperfusion.
Stroke. 1997;28:858–865.
131. Okada Y, Copeland BR, Hamann GF, Koziol JA, Cheresh DA, del
Zoppo GJ. Integrin avb3 is expressed in selected microvessels after focal
cerebral ischemia. Am J Pathol. 1996;149:37–44.
132. Baggiolini M, Dewald B, Moser B. Human chemokines: an update.
Annu Rev Immunol. 1997;15:675–705.
133. Liu T, Young PR, McDonnell PC, White RF, Barone FC, Feuerstein GZ.
Cytokine-induced neutrophil chemoattractant mRNA expressed in
cerebral ischemia. Neurosci Lett. 1993;164:125–128.
134. Watanabe K, Konishi K, Fujioka M, Kinoshita S, Nakagawa H. The
neutrophil chemoattractant produced by the rat kidney epithelioid cell
line NRK-52E is a protein related to CINC/KC/gro protein. J Biol Chem.
1989;264:19559–19563.
135. Yamasaki Y, Matsuo Y, Matsuura N, Onodera H, Itoyama Y, Kogure K.
Transient increase of cytokine-induced neutrophil chemoattractant, a
member of the interleukin-8 family, in ischemic brain areas after focal
ischemia in rats. Stroke. 1995;26:318–323.
136. Wang X, Yue TL, Barone FC, Feuerstein GZ. Monocyte chemoat-
tractant protein-1 messenger RNA expression in rat ischemic cortex.
Stroke. 1995;26:661–666.
137. Kim JS, Gautam SC, Chopp M, Zaloga C, Jones ML, Ward PA, Welch
KMA. Expression of monocyte chemoattractant protein-1 and macro-
phage inflammatory protein-1 after focal cerebral ischemia in the rat.
J Neuroimmunol. 1995;56:127–134.
138. Sica A, Wang JM, Colotta F, Dejana E, Mantovani A, Oppenheim JJ,
Larsen CG, Zachariae COC, Matsushima K. Monocyte chemotactic and
activating factor gene expression induced in endothelial cells by IL-1
and tumor necrosis factor. J Immunol. 1990;144:3034–3038.
139. Gourmala NG, Buttini M, Limonta S, Sauter A, Boddeke HWGM.
Differential and time-dependent expression of monocyte chemoat-
tractant protein-1 mRNA by astrocytes and macrophages in rat brain:
effects of ischemia and peripheral lipopolysaccharide administration.
J Neuroimmunol. 1997;74:35–44.
140. Saukkonen K, Sande S, Cioffe C, Wolpe S, Sherry B, Cerami A,
Tuomanen E. The role of cytokines in the generation of inflammation
and tissue damage in experimental gram-positive meningitis. J Exp Med.
1989;171:439–448.
141. Wang X, Yue T-L, Ohlstein EH, Sung C-P, Feuerstein GZ. Interferon-
inducible protein-10 involves vascular smooth muscle cell migration,
proliferation, and inflammatory response. J Biol Chem. 1996;271:
24286–24293.
142. Chopp M, Zhang RL, Chen H, Li Y, Jiang N, Rusche JR. Postischemic
administration of an anti-Mac-1 antibody reduces ischemic cell damage
after transient middle cerebral artery occlusion in rats. Stroke. 1994;25:
869–876.
143. Zhang ZG, Chopp M, Tang WX, Jiang N, Zhang RL. Postischemic
treatment (2–4 h) with anti-CD11b and anti-CD18 monoclonal anti-
bodies are neuroprotective after (2h) focal cerebral ischemia in the rat.
Brain Res. 1995;698:79–85.
144. Chen H, Chopp M, Zang RL, Bodzin G, Chen Q, Rusche JR, Todd RF.
Anti-CD11b monoclonal antibody reduces ischemic cell damage after
transient focal cerebral ischemia in rat. Ann Neurol. 1994;35:458–463.
145. Garcia JH, Liu K-F, Bree MP. Effects of CD11b/18 monoclonal
antibody on rats with permanent middle cerebral artery occlusion. Am J
Pathol. 1996;148:241–248.
146. Chopp M, Li Y, Jiang N, Zhang RL, Prostak J. Antibodies against
adhesion molecules reduce apoptosis after transient middle cerebral
artery occlusion in rat brain. J Cereb Blood Flow Metab. 1996;16:
578–584.
147. Zhang RL, Chopp M, Zaloga C, Jiang N, Jones ML, Miyasaka M, Ward
PA. Anti-ICAM-1 antibody reduces ischemic cell damage after transient
middle cerebral artery occlusion in the rat. Neurology. 1994;44:
1747–1751.
148. Matsuo Y, Onodera H, Shiga Y, Shozuhara H, Ninomiya M, Kihara T,
Tamatani T, Miyasaka M, Kogure K. Role of cell adhesion molecules in
brain injury after transient middle cerebral artery occlusion in the rat.
Brain Res. 1994;656:344–352.
149. Zhang RL, Chopp M, Jiang N, Tang WX, Prostak J, Manning AM,
Anderson DC. Anti-intercellular adhesion molecule-1 antibody reduces
ischemic cell damage after transient but not permanent middle cerebral
artery occlusion in the Wistar rat. Stroke. 1995;26:1438–1443.
150. Clark WM, Madden KP, Rothlein R, Zivin JA. Reduction of central
nervous system ischemic injury by monoclonal antibody to intercellular
adhesion molecule. J Neurosurg. 1991;75:623–627.
512 Cytokines and Adhesion Molecules in Cerebral Ischemia
 by guest on February 27, 2018
http://atvb.ahajournals.org/
D
ow
nloaded from
 
151. Jiang N, Moyle M, Soule H, Rote WE, Chopp M. Neutrophil inhibitory
factor is neuroprotective after focal ischemia in rats. Ann Neurol. 1995;
38:935–942.
152. Zhang RL, Chopp M, Tang WX, Zhang ZG, Putney SD, Starzyk RM.
Synthetic peptide derived from the Bordetella pertussis bacterium
reduces infarct volume after transient middle cerebral artery occlusion in
the rat. Neurology. 1996;46:1437–1441.
153. Ember JA, del Zoppo GJ, Mori E, Thomas WS, Copeland BR, Hugli TE.
Polymorphonuclear leukocyte behavior in a nonhuman primate focal
ischemia model. J Cereb Blood Flow Metab. 1994;14:1046–1054.
154. Baron JC, von Kummer R, del Zoppo GJ. Treatment of acute ischemic
stroke: challenging the concept of a rigid and universal time window.
Stroke. 1995;26:2219–2221.
155. Marchal G, Beaudouin V, Rioux P, de la Sayette V, Le Doze F, Viader
F, Derlon JM, Baron JC. Prolonged persistence of substantial volumes of
potentially viable tissue after stroke: a correlative PET-CT study with
voxel-based data analysis. Stroke. 1996;27:599–606.
156. Bowes MP, Rothlein R, Fagan SC, Zivin JA. Monoclonal antibodies
preventing leukocyte activation reduce experimental neurologic injury
and enhance efficacy of thrombolytic therapy. Neurology. 1995;45:
815–819.
157. Azzimondi G, Bassein L, Fiorani L, Nonino F, Montaguti U, Celin D,
Re G, D’Alessandro R. Variables associated with hospital arrival time
after stroke: effect of delay on the clinical efficiency of early treatment.
Stroke. 1997;28:537–542.
158. Aspey BS, Jessimer C, Pereira S, Harrison MJG. Do leukocytes have a
role in the cerebral no-reflow phenomenon? J Neurol Neurosurg Psy-
chiatry. 1989;52:526–528.
159. Takeshima R, Kirsch JR, Koehler RC, Gomoll AW, Traystman RJ.
Monoclonal leukocyte antibody does not decrease the injury of transient
focal cerebral ischemia in cats. Stroke. 1992;23:247–252.
160. Hayward NJ, Elliott PJ, Swayer SD, Bronson RT, Bartus RT. Lack of
evidence for neutrophil participation during infarct formation following
focal cerebral ischemia in the rat. Exp Neurol. 1996;139:188–202.
161. The Enlimomab Acute Stroke Trial Investigators, Sherman DG. The
Enlimomab Acute Stroke Trial: final results. Neurology. 1997;48:A270.
Abstract.
162. Hallenbeck JM, Frerichs KU. Stroke therapy: it may be time for an
integrated approach. Arch Neurol. 1993;50:768–770.
KEY WORDS: cerebral ischemia n cytokines n cell adhesion molecules
n leukocytes n therapy
Pantoni et al April 1998 513
 by guest on February 27, 2018
http://atvb.ahajournals.org/
D
ow
nloaded from
 
Leonardo Pantoni, Cristina Sarti and Domenico Inzitari
Therapeutic Perspectives
Cytokines and Cell Adhesion Molecules in Cerebral Ischemia: Experimental Bases and
Print ISSN: 1079-5642. Online ISSN: 1524-4636 
Copyright © 1998 American Heart Association, Inc. All rights reserved.
Greenville Avenue, Dallas, TX 75231
is published by the American Heart Association, 7272Arteriosclerosis, Thrombosis, and Vascular Biology 
doi: 10.1161/01.ATV.18.4.503
1998;18:503-513Arterioscler Thromb Vasc Biol. 
 http://atvb.ahajournals.org/content/18/4/503
World Wide Web at: 
The online version of this article, along with updated information and services, is located on the
  
 http://atvb.ahajournals.org//subscriptions/
at: 
is onlineArteriosclerosis, Thrombosis, and Vascular Biology  Information about subscribing to Subscriptions:
  
 http://www.lww.com/reprints
 Information about reprints can be found online at: Reprints:
  
document. Answer
Permissions and Rights Question andunder Services. Further information about this process is available in the
permission is being requested is located, click Request Permissions in the middle column of the Web page 
whichCopyright Clearance Center, not the Editorial Office. Once the online version of the published article for 
 can be obtained via RightsLink, a service of theArteriosclerosis, Thrombosis, and Vascular Biologyin
 Requests for permissions to reproduce figures, tables, or portions of articles originally publishedPermissions:
 by guest on February 27, 2018
http://atvb.ahajournals.org/
D
ow
nloaded from
 
